Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis
PLOS ONE · 13.11.2024 · 19 (11) · e0310696
DOI: 10.1371/journal.pone.0310696 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS ONE, online erschienen am 13.11.2024. Verfasst von Lingyan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Protection Center, The 926th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Kaiyuan, Yunan, Chi…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Drug Therapy, Combination, Ezetimibe, Hypercholesterolemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Statins are the gold standard in the treatment of dyslipidemia, significantly reducing the risk of cardiovascular disease.
Objective
To systematically review the efficacy and safety of Moderate-intensity Rosuvastatin Plus Ezetimibe compared with High-intensity Rosuvastatin in treating Composite Cardiovascular Events.
Methods
PubMed, Embase, Cochrane Library, CINAHL, Web of Science, China Knowledge Network, China Biological Literature Database, Wan Fang Database, and Weipu Database were searched to retrieve randomized controlled trials assessing the safety and efficacy of the two therapies from the time of construction to December 2023. The Jadad scale assessment tool was used to evaluate the quality of the included literature, and Review Manager 5.4 software was used for meta-analysis. The heterogeneity of outcomes was estimated by the I 2 test, where we applied risk ratios (RR) and 95% confidence intervals (CI) to assess dichotomous outcomes and mean difference (MD) and 95% CI to present continuous outcomes. We used funnel plots to assess study publication bias and sensitivity analysis was used to address significant clinical heterogeneity.
Results
The meta-analysis described 21 RCTs involving 24592 participants. The findings indicated that moderate-intensity statin combination therapy improved low-density lipoprotein cholesterol (LDL-C) (MD -8.06, 95% CI [-9.48, -6.64] p < 0.05), total cholesterol (TG) (MD -5.66, 95% CI [-8.51, -2.82] p < 0.05), and non-high-density lipoprotein cholesterol (non-HDL-C) (MD -17.04, 95% CI [-29.55, -4.54] p < 0.05) to a greater extent and superior in achieving LDL-C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Protection Center, The 926th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Kaiyuan, Yunan, China.
- Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali University, Dali, Yunnan Province, China.
- National-Local Joint Engineering Research Center of Entomoceutics, Dali University, Dali, Yunnan Province, China.
- College of Pharmacy Dali University, Dali, Yunnan, China.
ORCID-Profile: Lingyan Liu
Zitieren
APA
Liu, L., Deng, Y., Li, L., Yang, X., Yin, Z., & Lai, Y. (2024). Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis. PLOS ONE, 19(11), e0310696. https://doi.org/10.1371/journal.pone.0310696
Vancouver
Liu L, Deng Y, Li L, Yang X, Yin Z, Lai Y. Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis. PLOS ONE. 2024;19(11):e0310696. doi:10.1371/journal.pone.0310696
BibTeX
@article{Liu2024,
author = {Liu, Lingyan and Deng, Yongkun and Li, Lei and Yang, Xingbiao and Yin, Zhaoheng and Lai, Yong},
title = {Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {11},
pages = {e0310696},
doi = {10.1371/journal.pone.0310696}
}
EUVIMED